Published in JAMA on June 07, 2006
Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation (2009) 2.60
De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int (2015) 1.93
Experts' recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care (2015) 1.51
Ventricular Assist Device in Acute Myocardial Infarction. J Am Coll Cardiol (2016) 1.46
A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. Am Heart J (2010) 1.46
Mechanical circulatory support in cardiogenic shock - what every interventional cardiologist should know. Postepy Kardiol Interwencyjnej (2014) 1.11
Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc (2014) 1.06
Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Dtsch Arztebl Int (2012) 1.06
Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Crit Care (2011) 0.93
The challenges in the management of right ventricular infarction. Eur Heart J Acute Cardiovasc Care (2013) 0.91
Cardiogenic shock in ACS. Part 1: prediction, presentation and medical therapy. Nat Rev Cardiol (2011) 0.86
Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population. PLoS One (2013) 0.85
Impact of intra-aortic balloon pump on long-term mortality of unselected patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock. Postepy Kardiol Interwencyjnej (2014) 0.85
Outcome after surgery and percutaneous intervention for cardiogenic shock and left main disease. Ann Thorac Surg (2008) 0.85
[Ivabradine - a new therapeutic option for cardiogenic shock?]. Herz (2009) 0.83
Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol (2013) 0.83
Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract (2013) 0.82
Percutaneous coronary intervention for unprotected left main disease in very high risk patients: safety of drug-eluting stents. Heart Vessels (2010) 0.81
Percutaneous coronary intervention in cardiogenic shock complicating acute ST-elevation myocardial infarction-a single centre experience. Indian Heart J (2012) 0.81
Radial artery applanation tonometry for continuous noninvasive arterial blood pressure monitoring in the cardiac intensive care unit. Clin Res Cardiol (2015) 0.79
Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock. Herz (2011) 0.78
Interventional therapies in acute myocardial infarction complicated by cardiogenic shock. Herz (2016) 0.77
Long-term survival after mitral valve surgery for post-myocardial infarction papillary muscle rupture. J Cardiothorac Surg (2015) 0.76
Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. Crit Care (2012) 0.76
Decade-Long Trends (2001-2011) in the Incidence and Hospital Death Rates Associated with the In-Hospital Development of Cardiogenic Shock after Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes (2016) 0.76
In-hospital and six-month outcomes of elderly patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. ARYA Atheroscler (2016) 0.75
Cardiogenic shock in acute coronary syndromes-miles to go? Indian Heart J (2012) 0.75
High-risk percutaneous coronary intervention in the era of public reporting: clinical and ethical considerations in the care of an elderly patient with critical left main disease and shock. Circulation (2014) 0.75
Risk stratification for ST segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. World J Cardiol (2014) 0.75
An unusual case of renal calculi leading to myocardial infarction and cardiogenic shock. World J Emerg Med (2017) 0.75
Optimal Timing of Percutaneous Coronary Intervention for Nonculprit Vessel in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Korean Circ J (2016) 0.75
Evaluating surrogate marker information using censored data. Stat Med (2017) 0.75
Early revascularization improved long-term survival after myocardial infarction with cardiogenic shock. ACP J Club (2006) 0.75
Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials. Acute Card Care (2011) 0.75
Conservative pharmacotherapy vs. staged percutaneous coronary intervention for non-culprit vessels in patients with ST-segment elevation myocardial infarction. Exp Ther Med (2016) 0.75
Routine pretreatment with abciximab versus standard periprocedural therapy in mechanically ventilated cardiogenic shock patients undergoing primary percutaneous coronary intervention: Subanalysis of the PRAGUE-7 study. Exp Clin Cardiol (2013) 0.75
In-Hospital Outcome of Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Results from Royal Hospital Percutaneous Coronary Intervention Registry, Oman. Oman Med J (2016) 0.75
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med (1999) 6.93
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation (2004) 6.34
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA (2000) 6.00
A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol (1996) 2.60
Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA (2005) 2.56
Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med (1999) 2.46
One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10
Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med (1991) 1.99
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol (2004) 1.77
Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.66
Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J (2003) 1.66
Long-term MI outcomes at hospitals with or without on-site revascularization. JAMA (2001) 1.66
Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol (2005) 1.58
Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary intervention. Am Heart J (2003) 1.21
SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. Am Heart J (1999) 1.15
Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J (2003) 1.14
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. Circulation (1999) 1.02
Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol (2002) 1.02
Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. Am J Cardiol (2001) 0.91
Cause of death analysis in the NHLBI PTCA Registry: results and considerations for evaluating long-term survival after coronary interventions. J Am Coll Cardiol (1997) 0.91
Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invasive Cardiol (2003) 0.88
Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population. Am Heart J (2003) 0.86
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 22.04
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
Universal definition of myocardial infarction. Circulation (2007) 11.69
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Universal definition of myocardial infarction. Eur Heart J (2007) 9.04
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Universal definition of myocardial infarction. J Am Coll Cardiol (2007) 8.68
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med (2012) 6.27
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med (2007) 6.22
Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med (2010) 5.43
Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11
Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol (2010) 5.09
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA (2006) 4.51
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med (2012) 4.47
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation (2010) 3.95
Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation (2006) 3.94
Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med (2003) 3.28
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. JACC Cardiovasc Interv (2012) 3.13
Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation (2010) 3.13
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA (2007) 3.07
Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll Cardiol (2008) 2.91
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation (2010) 2.88
Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation (2006) 2.88
Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet (2013) 2.82
Impact of delays to cardiac surgery after failed angioplasty and stenting. J Am Coll Cardiol (2004) 2.81
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Impact of post-implant SAPIEN XT geometry and position on conduction disturbances, hemodynamic performance, and paravalvular regurgitation. JACC Cardiovasc Interv (2013) 2.75
Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. Eur J Cardiothorac Surg (2006) 2.61
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med (2002) 2.49
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 2.47
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol (2008) 2.46
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. Lancet (2003) 2.45
Percutaneous closure of prosthetic paravalvular leaks: case series and review. Catheter Cardiovasc Interv (2006) 2.34
Design and methodology of the Occluded Artery Trial (OAT). Am Heart J (2005) 2.26
Management of vascular access in transcatheter aortic valve replacement: part 1: basic anatomy, imaging, sheaths, wires, and access routes. JACC Cardiovasc Interv (2013) 2.20
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation (2008) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA (2005) 2.17
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol (2007) 2.14
Design and rationale of a randomized trial comparing the Blalock-Taussig and right ventricle-pulmonary artery shunts in the Norwood procedure. J Thorac Cardiovasc Surg (2008) 2.12
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med (2002) 2.09
Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Eur Heart J (2005) 2.08
Coronary obstruction following transcatheter aortic valve-in-valve implantation for failed surgical bioprostheses. Catheter Cardiovasc Interv (2011) 2.06
Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol (2009) 2.05
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J (2008) 2.04
Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data. Ann Intern Med (2002) 2.03
Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol (2011) 2.02
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol (2012) 2.02